US Supreme Court Asked To Review Timing Of Biosimilar Entry
This article was originally published in The Pink Sheet Daily
Executive Summary
In Zarxio case, Sandoz petitions high court to determine whether notice of biosimilar commercial marketing can be given before FDA approval; court may await rulings in pending cases interpreting the biosimilars statute.
You may also be interested in...
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.
Biosimilar Launch Notification May Head Back To Court
Apotex wants Supreme Court to say that firm doesn't have to wait until FDA licensure of its pegfilgrastim and filgrastim biosimilars to provide Amgen 180-day notice of commercial marketing; Solicitor General has yet to weigh in on similar Sandoz petition.